Skip to content
FoodEdge
Technical due diligence

Food biotech due diligence: proof before you invest, license or acquire

Independent technical due diligence in food biotech and nutrition, for investment teams and corporate R&D in Europe and APAC. We read the data room, test the claims against published evidence and tell you what holds, what does not and what is still missing.

Three questions we answer

Will it scale at the cost the plan assumes?

Titre, yield, downstream recovery, contract manufacturing and plant capacity, checked against the cost model in the deck.

Will the claims and the regulatory path hold in your markets?

Nutrition and health claims, novel food status and approval timelines in the EU, UK, US and APAC markets that matter to the deal.

Which evidence is missing from the data room?

A plain list of what has not been shown yet, and the questions to put to management before you commit.

Formats

Business engagements. EUR, excluding applicable taxes. Payment by invoice.

Evidence Check

€4,900 fixed

It answers one narrow question: does the claim have evidence strong enough for the decision you are about to make?

  • A structured note in about a week (5 to 8 working days)
  • The exact claim, and the data strength: strong, moderate, weak or missing
  • The gaps that matter
  • The single best next action: proceed, pause or test this
Ask about an Evidence Check

Red-flag review

€7,500 fixed

A desk-based review with a fixed scope, for a decision that cannot wait for a full study.

  • Review of the data room you share with us
  • One call with the management team
  • A written memo: findings, limits and the decision points for your committee
  • Delivered in 5 to 10 working days from receipt of the data room

Full technical due diligence

Quoted per case

For an investment or acquisition where the technology carries the deal.

  • 3 to 6 weeks
  • Interviews with the team and, where needed, outside experts
  • A site or contract manufacturer visit
  • Review of the technical and cost model

Decision Sprint

€9,900, up to 8 people

For corporate teams who need to decide on a technology, a partner or a build-or-license question together. Two three-hour sessions within ten working days and a 3 to 5 page decision memo.

See the Decision Sprint

How we work

Every finding is written in three parts. Finding: what the evidence shows. Limit: what it cannot show, and how sure we are. Decision: what that means for your investment, licence or acquisition. We name every source, separate the company's own data from independent evidence and state the uncertainty in plain words. Where the evidence is not there, the memo says so.

Who does the work

The work is led by Dr Adam M. Adamek, Editor-in-Chief of FoodEdge.

Industry experience behind FoodEdge includes research and innovation leadership at Danone Research, consumer science and R&D leadership at Mondelēz International, R&D and nutrition innovation at Mars / foodspring, R&D and quality leadership at Pharma Nord, and market research and competitive intelligence at MSD (Merck & Co.).

Expert evaluation for REA / European Commission. Senior expert in evidence-based innovation at ClearGate Cambridge.

Startup Challenge judge at Fi Europe and Vitafoods.

Independence

We check conflicts before every engagement and name any relevant role in the engagement letter.